Rezolute (RZLT) shares are poised to show strength towards upcoming ersodetug catalysts, with Sunrize phase 3 trial in congenital hyperinsulinism program update slated for mid-September and topline data from the Uplift phase 3 study in tumor HI expected in H2, Wedbush said in a Tuesday note.

Wedbush said it continues to believe that the requirement for a small supplemental study, to be actively ongoing at the time of biologics license application with currently available data, could be the most likely path forward for ersodetug in congenital HI.

Additionally, the US Food and Drug Administration's recognition of the increasing use of continuous glucose monitor in clinical practice could bode well for the agency's feedback on ersodetug's pathway forward in congenital HI, according to the note.

Wedbush maintained its outperform rating with a $6 price target.

Price: 5.08, Change: +0.07, Percent Change: +1.40